Form 4: Gossamer Bio Director Nathan Steven D Granted 115,000 Stock Options

Gossamer Bio, Inc. Director Nathan Steven D was granted 115,000 stock options at an exercise price of $1.36 as part of the company's Non-Employee Director Compensation Program.

Summary

• Nathan Steven D, a Director of Gossamer Bio, Inc. (GOSS), was granted 115,000 stock options.
• The stock options have an exercise price of $1.36 per share.
• The grant date for these options was June 25, 2025.
• The options were awarded under the company's Non-Employee Director Compensation Program.
• The options will become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date (June 25, 2026) or (b) the next annual meeting of Gossamer Bio's stockholders.
• Vesting is contingent upon Mr. Nathan's continued service on the board of directors through the vesting date.
• The expiration date for these stock options is June 24, 2035.
• Following this transaction, Nathan Steven D beneficially owns 115,000 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it indicates standard corporate governance and aligns director interests with shareholders, but it's a routine compensation event with no direct impact on operational or financial performance.

Positives

• The grant of stock options to Director Nathan Steven D aligns his interests with those of the shareholders, as the value of his compensation is tied to the company's stock performance.
• This is a standard practice for non-employee director compensation, indicating a structured approach to governance and incentivization.

Risks

• The value of the stock options is subject to the future market price of Gossamer Bio's common stock, meaning the options may not be 'in the money' if the stock price does not exceed the exercise price of $1.36.
• The vesting of the options is contingent on the director's continued service, posing a risk of forfeiture if service ceases before vesting.

Future Outlook

The stock options granted to Director Nathan Steven D are set to vest on the first anniversary of the grant date (June 25, 2026) or at the next annual meeting of stockholders, whichever occurs first, provided he continues his service on the board.

Industry Context

The granting of stock options to non-employee directors is a common compensation practice across various industries, including biotechnology, to attract and retain qualified board members and align their financial interests with long-term shareholder value. This filing reflects a routine compensation event within the biotech sector.

Comparison to Industry Standards

• The use of stock options as a component of non-employee director compensation is a widely accepted industry standard, particularly in growth-oriented sectors like biotechnology where equity incentives are prevalent.
• The vesting schedule, tied to continued service and an annual milestone, is typical for such grants, aiming to ensure long-term commitment from board members.

Corporate Governance

Related Party Transactions

• The grant of 115,000 stock options to Nathan Steven D, a Director of Gossamer Bio, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial incentives with shareholder interests, as the value of the options depends on the company's stock price performance.
• Employees: No direct impact on employees is indicated by this specific filing.

Next Steps

• The stock options will vest on the first anniversary of the grant date (June 25, 2026) or at the next annual meeting of stockholders, subject to the director's continued service.

Key Dates

Keywords

Stock Option, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Gossamer Bio, GOSS, Non-Employee Director, Vesting